Loading stock data…
CSTL
$24.81+0.32 (+1.31%)
Market ClosedLast close May 1
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Castle Biosciences, Inc. in the Healthcare sector is trading at $24.81. The stock is currently 44% below its 52-week high of $44.28, remaining 12.7% below its 200-day moving average. Technical signals show neutral RSI of 59 and bullish MACD crossover, explaining why CSTL maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 59) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$24.81
Potential Upside
5%
Whystock Fair Value$26.05
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$760.43M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.01%
Volume
Today's trading volume
176,942
Recent News
KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration
Kymera Therapeutics tops Q1 revenue estimates on strong Gilead collaboration, as pipeline advances and KT-200 milestone deal boost outlook.
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum
Agios shares jump 13% as Q1 revenues surge 138% on Aqvesme launch and Pyrukynd growth, while pipeline advances and SCD filing plans take shape.
VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs
Viking Therapeutics posts a wider Q1 loss as R&D spend jumps on Phase III obesity drug work, while it advances VK2735 studies and preps oral late-stage study.
How Revenue Assumptions Are Rewriting The Story For Castle Biosciences (CSTL)
Castle Biosciences is back in focus as one firm’s price target shift from US$35 to US$52 draws attention to how small changes in revenue assumptions can reshape upside scenarios. That move is part of a broader pattern, where analysts are tying targets more closely to 2026 revenue frameworks and the company’s preliminary 2025 revenue disclosure. As you read on, you will see how to track these evolving inputs so you can follow the narrative as it develops. Analyst Price Targets don't always...
Castle Biosciences Highlights DECIDE Study: DecisionDx-Melanoma Refines SLNB and Recurrence Risk
Castle Biosciences (NASDAQ:CSTL) executives and clinical collaborators used a DecisionDx-Melanoma webcast to review results from the multicenter DECIDE study, which the company said was recently published in Future Oncology. The discussion focused on how the company’s 31-gene expression profile (31-